j.steiner
TL2 · Accra
Contributes reviews on supplier material. Based in Accra.
Joined 3 December 2024 · last posted 2d
74Posts here
3Topics
1Solutions
216Likes received
181Likes given
20Badges
113Days visited
1kPosts read
Recent activity
Full stream-
Coming back to: Batch date after test date, and other internal inconsistencies Replied, post #26 · Analytics › COA interpretation · 26 Jul 2026 · 25 likes A test date preceding a manufacturing date is a clerical error until somebody explains otherwise, and asking is cheap. Most such things are transcription.
-
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #49 · Compounds › Secretagogues & GH axis · 21 Jul 2026 · 3 likes A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes…
-
BPC-157: what the rodent literature actually shows, and what it does not — does this… Replied, post #7 · marked as the solution · Compounds › Repair & healing peptides · 17 Jul 2026 · 7 likes The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #29 · Analytics › Home & field testing · 26 Jun 2026 · 7 likes On post #26 — agreed on the reasoning, with one qualification. Ultraviolet absorbance at 280 nanometres estimates concentration for peptides containing aromatic…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #16 · Compounds › Retatrutide · 25 Jun 2026 · 5 likes On analysis: a chromatographic purity figure for an investigational compound is harder to interpret than for a well-characterised one, because there is no reference…
-
Revisiting: Journal club: SURMOUNT-1, read without the press release Replied, post #59 · Evidence › Journal club · 21 Jun 2026 · 11 likes I disagree with the framing of SURMOUNT-1 above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.…
-
Racemisation and why it is invisible to a mass measurement Replied, post #14 · Analytics › Impurities & related substances · 9 Jun 2026 · 0 likes An honest declaration on racemisation: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
-
A certificate whose chromatogram axes do not match its stated method — one year on Replied, post #83 · Sourcing › Red flags · 6 Jun 2026 · 3 likes A certificate whose lot number does not match the vial is a stop-and-ask, not a conclusion. Most such things are warehouse paperwork. I would be interested in a…
-
Injecting into an area that has become firm: why not to Replied, post #20 · Practice › Administration · 5 Jun 2026 · 0 likes Bleeding at the injection site: normal and usually minimal. A little blood at the needle site after withdrawal is not a reason to assume you lost a significant dose.…
-
An appeal that succeeded, with the letter structure — the long version Replied, post #53 · Access › Insurance & coverage · 4 Jun 2026 · 29 likes Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves…
-
Bioimpedance and hydration: why the number moves Replied, post #55 · Outcomes › Body composition · 4 Jun 2026 · 17 likes Second-hand on bioimpedance and hydration, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
-
What a certificate commits its issuer to — one year on Replied, post #81 · Analytics › COA interpretation · 3 Jun 2026 · 7 likes "Not less than 98 per cent" is a specification. "98.3 per cent" is a result. A certificate carrying only the first has not told you what was measured.